Cited by 1,752Phagocytosis and Immune RegulationAcute Myeloid Leukemia ResearchFlavonoids in Medical Research

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Open access

Majeti, Ravindra, Chao, Mark P., Alizadeh, Ash A., Pang, Wendy W., Jaiswal, Siddhartha, Gibbs, Kenneth D., van Rooijen, Nico, Weissman, Irving L.·2009·Cell

DOI 10.1016/j.cell.2009.05.045PMC PMC2726837

Open this paper in CoChat — free account

Abstract

Acute myeloid leukemia (AML) is organized as a cellular hierarchy initiated and maintained by a subset of self-renewing leukemia stem cells (LSC). We hypothesized that increased CD47 expression on human AML LSC contributes to pathogenesis by inhibiting their phagocytosis through the interaction of CD47 with an inhibitory receptor on phagocytes. We found that CD47 was more highly expressed on AML LSC than their normal counterparts, and that increased CD47 expression predicted worse overall survival in three independent cohorts of adult AML patients. Furthermore, blocking monoclonal antibodies directed against CD47 preferentially enabled phagocytosis of AML LSC and inhibited their engraftment in vivo. Finally, treatment of human AML LSC-engrafted mice with anti-CD47 antibody depleted AML and targeted AML LSC. In summary, increased CD47 expression is an independent, poor prognostic factor that can be targeted on human AML stem cells with blocking monoclonal antibodies capable of enabling phagocytosis of LSC.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2009.05.045

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Self-citation
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
Bonnet, D. A., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 7,197
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
Grimwade, D. J., Walker, H., Oliver, F., Wheatley, K., Harrison, C. J., Harrison, G., Rees, J., Hann, I. M., Stevens, R., Burnett, A. K., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,649
Role of CD47 as a Marker of Self on Red Blood Cells
Oldenborg, P., Zheleznyak, A., Fang, Y., Lagenaur, C. F., Gresham, H. D., & Lindberg, F. P. (2000) · Science · doi:10.1126/science.288.5473.2051 · Cited by 2,018
Cancer Stem Cells
Jordan, C. T., Guzmán, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,748
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,594
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D. J., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,578
Self-citation
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485 · cited 2×
“Consistent with this hypothesis, we have shown that pre-leukemic mutations occur in a clonal HSC population, eventually leading to the development of LSC at the MPP stage in AML or the granulocyte-macrophage progenitor (GMP) stage in myeloid blast crisis chronic myeloid leukemia (CML) (Jamieson et al., 2004; Miyamoto…”
BackgroundSelf-citation
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells.
Lessard, J., & Sauvageau, G. (2003) · Nature · doi:10.1038/nature01572 · Cited by 1,452

Show all 47 references

Sorted by citations

Items 501–600 of 1,001

Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model
Hua, T., Qian, P., Wang, F., Yu, H., & Guo, Y. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14900505020895 · Cited by 61
Clearance of Apoptotic Cells by Tissue Epithelia: A Putative Role for Hepatocytes in Liver Efferocytosis
Davies, S. P., Reynolds, G. M., & Stamataki, Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00044 · Cited by 61
Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation
Schwartz, A. L., Nath, P. R., Allgäuer, M., Lessey-Morillon, E. C., Sipes, J. M., Ridnour, L. A., Morillon, Y. M., Yu, Z., Restifo, N. P., & Roberts, D. D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02397-7 · Cited by 61
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
Peluso, M. O., Adam, A., Armet, C. M., Zhang, L., O’Connor, R. W., Lee, B. H., Lake, A. C., Normant, E., Chappel, S. C., Hill, J. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000413 · Cited by 61
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
Valent, P., Sadovnik, I., Eisenwort, G., Bauer, K., Herrmann, H., Gleixner, K. V., Schulenburg, A., Rabitsch, W., Sperr, W. R., & Wolf, D. G. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174233 · Cited by 60
CD200 expression marks leukemia stem cells in human AML
Ho, J., Dobson, S. M., Voisin, V., McLeod, J. L., Kennedy, J. A., Mitchell, A., Jin, L., Eppert, K., Bader, G. D., Minden, M. D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001802 · Cited by 62
Macrophages in Acute Myeloid Leukaemia: Significant Players in Therapy Resistance and Patient Outcomes
Miari, K. E., Guzmán, M. L., Wheadon, H., & Williams, M. T. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.692800 · Cited by 62
Metabolic reprogramming of macrophages in cancer therapy
Wang, X., Zhang, S., Xue, D., Neculai, D., & Zhang, J. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.08.009 · Cited by 60
TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells
Kikushige, Y., & Miyamoto, T. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1433-6 · Cited by 61
Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment
Guo, Y., Feng, K., Wang, Y., & Han, W. (2017) · Protein & Cell · doi:10.1007/s13238-017-0394-6 · Cited by 60
Targeting mitochondrial respiration for the treatment of acute myeloid leukemia
Carter, J. L., Hege-Hurrish, K., Kalpage, H. A., Edwards, H. J., Hüttemann, M., Taub, J. W., & Ge, Y. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114253 · Cited by 61
Warburg Effect Is a Cancer Immune Evasion Mechanism Against Macrophage Immunosurveillance
Chen, J., Cao, X., Li, B., Zhao, Z., Chen, S., Lai, S. W. T., Muend, S., Nossa, G., Wang, L., Guo, W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.621757 · Cited by 59
Targeting macrophages for enhancing CD47 blockade–elicited lymphoma clearance and overcoming tumor-induced immunosuppression
Cao, X., Wang, Y., Zhang, W., Zhong, X., Gunes, E. G., Dang, J., Wang, J., Epstein, A. L., Querfeld, C., Sun, Z., et al. (2022) · Blood · doi:10.1182/blood.2021013901 · Cited by 59
A DNA Logic Circuit Equipped with a Biological Amplifier Loaded into Biomimetic ZIF‐8 Nanoparticles Enables Accurate Identification of Specific Cancers In Vivo
Wei, K., He, M., Zhang, J., Zhao, C., Nie, C., Zhang, T., Liu, Y., Chen, T., Jiang, J., & Chu, X. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202307025 · Cited by 60
Leukemia stem cells
Testa, U. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1118-7 · Cited by 60
Urothelial carcinoma: Stem cells on the edge
Brandt, W. D., Matsui, W. H., Rosenberg, J. E., He, X., Ling, S., Schaeffer, E. M., & Berman, D. M. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9187-6 · Cited by 59
The complex and central role of interferon‐γ in graft‐versus‐host disease and graft‐versus‐tumor activity
Wang, H., & Yang, Y. (2014) · Immunological Reviews · doi:10.1111/imr.12151 · Cited by 59
Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20
Weiskopf, K., Anderson, K. L., Ito, D., Schnorr, P. J., Tomiyasu, H., Ring, A. M., Bloink, K., Efe, J. A., Rue, S. M., Lowery, D. E., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0105 · Cited by 59
Self-citation
Maea expressed by macrophages, but not erythroblasts, maintains postnatal murine bone marrow erythroblastic islands
Wei, Q., Boulais, P. E., Zhang, D., Pinho, S., Tanaka, M., & Frenette, P. S. (2019) · Blood · doi:10.1182/blood-2018-11-888180 · Cited by 59
Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy
Zhao, P., Qiu, L., Zhou, S., Li, L., Qian, Z., & Zhang, H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s295565 · Cited by 59
Biomimetic nanoprobe-augmented triple therapy with photothermal, sonodynamic and checkpoint blockade inhibits tumor growth and metastasis
Lin, X., He, T., Tang, R., Li, Q., Wu, N., Zhou, Y., He, H., Wan, L., Huang, J., Jiang, Q., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01287-y · Cited by 58
Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy
Xu, S., Wang, C., Yang, L., Wu, J., Li, M., Xiao, P., Xu, Z., Xu, Y., & Wang, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199631 · Cited by 59
Immunological nanomaterials to combat cancer metastasis
Pan, Y., Cheng, J., Zhu, Y., Zhang, J., Fan, W., & Chen, X. S. (2024) · Chemical Society Reviews · doi:10.1039/d2cs00968d · Cited by 58
Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments
Gibbs, K. D., Gilbert, P. M., Sachs, K., Zhao, F., Blau, H. M., Weissman, I. L., Nolan, G. P., & Majeti, R. (2011) · Blood · doi:10.1182/blood-2010-07-298232 · Cited by 58
Self-citation
Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: Novel agents and approaches currently in clinical trials
Sasine, J. P., & Schiller, G. J. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.07.002 · Cited by 58
Immunotherapy Targets in Pediatric Cancer
Orentas, R. J., Lee, D. W., & Mackall, C. L. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00003 · Cited by 61
Immune Response Against Tumor Antigens Expressed on Human Cancer Stem-Like Cells/Tumor-Initiating Cells
Hirohashi, Y., Torigoe, T., Inoda, S., Takahashi, A., Morita, R., Nishizawa, S., Tamura, Y., Suzuki, H., Toyota, M., & Sato, N. (2010) · Immunotherapy · doi:10.2217/imt.10.10 · Cited by 59
The variety of leukemic stem cells in myeloid malignancy
Wiseman, D. H., Greystoke, B., & Somervaille, T. C. P. (2013) · Oncogene · doi:10.1038/onc.2013.269 · Cited by 59
Phagoptosis - Cell Death By Phagocytosis - Plays Central Roles in Physiology, Host Defense and Pathology
Brown, G. C., Vilalta, A., & Fricker, M. (2015) · Current Molecular Medicine · doi:10.2174/156652401509151105130628 · Cited by 60
Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy
Feliz‐Mosquea, Y. R., Christensen, A. A., Wilson, A. S., Westwood, B. M., Varagić, J., Meléndez, G. C., Schwartz, A. L., Chen, Q., Griner, L. A. M., Guha, R., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4884-x · Cited by 58
Cancer stem cell self-renewal as a therapeutic target in human oral cancer
Hu, J., Mirshahidi, S., Simental, A., Lee, S. C., Filho, P. A., Peterson, N. R., Duerksen-Hughes, P. J., & Yuan, X. (2019) · Oncogene · doi:10.1038/s41388-019-0800-z · Cited by 58
Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice
Li, Y., Zhang, M., Wang, X., Liu, W., Wang, H., & Yang, Y. (2020) · Nature Communications · doi:10.1038/s41467-019-14102-4 · Cited by 58
Cancer Immunosurveillance by T Cells
Rao, S., Gharib, K., & Han, A. S. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.08.001 · Cited by 60
The macrophage checkpoint CD47 : SIRPα for recognition of ‘self’ cells: from clinical trials of blocking antibodies to mechanobiological fundamentals
Andrechak, J. C., Dooling, L. J., & Discher, D. E. (2019) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2018.0217 · Cited by 57
The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapy
Zhao, J., Zhong, S., Niu, X., Jiang, J., Zhang, R., & Li, Q. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12804 · Cited by 60
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Armengol, M., Santos, J. C., Fernández-Serrano, M., Profitós-Pelejà, N., Ribeiro, M. L., & Roué, G. (2021) · Cancers · doi:10.3390/cancers13020214 · Cited by 61
Structure of the human marker of self 5-transmembrane receptor CD47
Fenalti, G., Villanueva, N., Griffith, M. T., Pagarigan, B., Lakkaraju, S. K., Huang, R. Y. ‐., Ladygina, N., Sharma, A., Mikolon, D., Abbasian, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25475-w · Cited by 57
The rarity of ALDH + cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients
Hoang, V. T., Buss, E. C., Wang, W., Hoffmann, I., Raffel, S., Zepeda‐Moreno, A., Baran, N., Wuchter, P., Eckstein, V., Trumpp, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29410 · Cited by 57
CD47: a new player in phagocytosis and xenograft rejection
Navarro–Álvarez, N., & Yang, Y. (2011) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.83 · Cited by 57
Hypothesis: Tim-3/Galectin-9, A New Pathway for Leukemia Stem Cells Survival by Promoting Expansion of Myeloid-Derived Suppressor Cells and Differentiating into Tumor-Associated Macrophages
Gao, L., Yu, S., & Zhang, X. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-9900-0 · Cited by 57
MiRNAs at the Crossroads between Innate Immunity and Cancer: Focus on Macrophages
Curtale, G. (2018) · Cells · doi:10.3390/cells7020012 · Cited by 58
Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades
Kantarjian, H. M., Short, N. J., Fathi, A. T., Marcucci, G., Ravandi, F., Tallman, M. S., Wang, E. S., & Wei, A. H. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.05.016 · Cited by 56
Turning enemies into allies—reprogramming tumor-associated macrophages for cancer therapy
Molgora, M., & Colonna, M. (2021) · Med · doi:10.1016/j.medj.2021.05.001 · Cited by 56
Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors
Zhang, J., Wang, S., Zhang, D. D., He, X., Wang, X., Han, H., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1230893 · Cited by 56
CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation
Chen, S., Wang, Y., Dang, J., Song, N., Chen, X., Wang, J., Huang, G. N., Brown, C. E., Yu, J., Weissman, I. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59326-9 · Cited by 60
Self-citation
DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders
Sato, H., Wheat, J. C., Steidl, U. G., & Ito, K. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00187 · Cited by 59
CD47-ligation induced cell death in T-acute lymphoblastic leukemia
Leclair, P., Liu, C.-C., Monajemi, M., Reid, G. S. D., Sly, L. M., & Lim, C. J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0601-2 · Cited by 56
CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes
Kosaka, A., Ishibashi, K., Nagato, T., Kitamura, H., Fujiwara, Y., Yasuda, S., Nagata, M., Harabuchi, S., Hayashi, R., Yajima, Y., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200792 · Cited by 58
The Iron Curtain: Macrophages at the Interface of Systemic and Microenvironmental Iron Metabolism and Immune Response in Cancer
DeRosa, A., & Leftin, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.614294 · Cited by 58
Unveiling the potential of CLL-1: a promising target for AML therapy
Samarkhazan, H. S., Zehtabcheh, S., Seraji, H. R., Beqaj, S., Tayefeh, S., Mohammadi, M. H., & Aghaei, M. (2025) · Biomarker Research · doi:10.1186/s40364-025-00738-6 · Cited by 55
Immunosurveillance as a regulator of tissue homeostasis
Senovilla, L., Galluzzi, L., Zitvogel, L., & Kroemer, G. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.06.005 · Cited by 57
CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis
Galli, S., Zlobec, I., Schürch, C. M., Perren, A. A., Ochsenbein, A. F., & Banz, Y. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.04.007 · Cited by 55
Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
Tavor, S., & Petit, I. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.07.001 · Cited by 56
Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer
Fucikova, J. P., Kašíková, L., Truxová, I., Laco, J., Škapa, P., Ryška, A., & Špíšek, R. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.11.006 · Cited by 58
Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
Fleischmann, M., Schnetzke, U., Hochhaus, A., & Scholl, S. (2021) · Cancers · doi:10.3390/cancers13225722 · Cited by 59
Brain Tumor Cell Membrane‐Coated Lanthanide‐Doped Nanoparticles for NIR‐IIb Luminescence Imaging and Surgical Navigation of Glioma
Wang, Z., Zhang, M., Chi, S., Zhu, M., Wang, C., & Liu, Z. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200521 · Cited by 54
MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
Stroopinsky, D., Rosenblatt, J. M., Ito, K., Mills, H., Yin, L., Rajabi, H. N., Vasir, B., Kufe, T., Luptakova, K., Arnason, J. E., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0677 · Cited by 54
CD47 activation-induced UHRF1 over-expression is associated with silencing of tumor suppressor gene p16INK4A in glioblastoma cells.
Boukhari, A., Alhosin, M., Bronner, C., Sagini, K., Truchot, C., Sick, É., Schini‐Kerth, V. B., André, P., Mély, Y., Mousli, M., et al. (2015) · PubMed · Cited by 54
Tumor propagating cells: drivers of tumor plasticity, heterogeneity, and recurrence
Vessoni, A. T., Filippi‐Chiela, E. C., Lenz, G., & Batista, L. F. Z. (2019) · Oncogene · doi:10.1038/s41388-019-1128-4 · Cited by 59
Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling
Nguyen, K. B., & Spranger, S. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201908224 · Cited by 55
The onco-immunological implications of Fusobacterium nucleatum in breast cancer
van der Merwe, M., van Niekerk, G., Botha, A., & Engelbrecht, A. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.02.007 · Cited by 54
The CD47-SIRPα axis is a promising target for cancer immunotherapies
Hao, Y., Zhou, X., Li, Y., Li, B., & Lei, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110255 · Cited by 54
Taurine from tumour niche drives glycolysis to promote leukaemogenesis
Sharma, S., Rodems, B. J., Baker, C. D., Kaszuba, C. M., Franco, E. I., Smith, B. R., Ito, T., Swovick, K., Welle, K. A., Zhang, Y., et al. (2025) · Nature · doi:10.1038/s41586-025-09018-7 · Cited by 53
Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy
Gu, K., Liang, T., Hu, L., Zhao, Y., Ying, W., Zhang, M., Chen, Y., Liang, B., Lin, X., Zhang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67674-9 · Cited by 54
CD47 Promotes Human Glioblastoma Invasion Through Activation of the PI3K/Akt Pathway
Liu, X., Wu, X., Wang, Y., Li, Y., Chen, X., Yang, W., & Jiang, L. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15155538502359 · Cited by 53
Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer
Sugimura‐Nagata, A., Koshino, A., Inoue, S., Nagano-Matsuo, A., Komura, M., Riku, M., Ito, H., Inoko, A., Murakami, H., Ebi, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052690 · Cited by 53
Antibody:CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylation
Suter, E. C., Schmid, E. M., Harris, A. R., Voets, E., Francica, B. J., & Fletcher, D. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109587 · Cited by 53
Cancer Therapy Targeting CD47/SIRPα
Dizman, N., & Buchbinder, E. I. (2021) · Cancers · doi:10.3390/cancers13246229 · Cited by 53
Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response
Stirling, E. R., Terabe, M., Wilson, A. S., Kooshki, M., Yamaleyeva, L. M., Alexander‐Miller, M. A., Zhang, W., Miller, L. D., Triozzi, P. L., & Soto‐Pantoja, D. R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004712 · Cited by 52
An Overview of Targeted Therapies in Acute Myeloid Leukemia
Turkalj, S., Radtke, F. A., & Vyas, P. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000914 · Cited by 54
Enhanced tumor self-targeting of lemon-derived extracellular vesicles by embedding homotypic cancer cell membranes for efficient drug delivery
Yang, L., Liang, G.-W., Cai, B., Xu, K., Zhao, Y., Xie, X., Zhang, Y.-L., Li, C.-Q., & Zhang, G. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03161-z · Cited by 52
Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia
Yang, K. Y., Xu, J., Liu, Q., Li, J., & Xi, Y. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.10.021 · Cited by 52
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinicPreprint
Bewersdorf, J. P., & Abdel-Wahab, O. I. (2022) · Genes & Development · doi:10.1101/gad.349368.122 · Cited by 53
Targeting the innate immune system in pediatric and adult AML
Perzolli, A., Koedijk, J. B., Zwaan, C. M., & Heidenreich, O. T. (2024) · Leukemia · doi:10.1038/s41375-024-02217-7 · Cited by 55
Microglia and macrophages in glioblastoma: landscapes and treatment directions
Solomou, G., Young, A. M. H., & Bulstrode, H. J. C. J. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13657 · Cited by 54
Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction
Verona, F., Bella, S. D., Schirano, R., Manfredi, C., Angeloro, F., Bozzari, G., Todaro, M., Giannini, G., Stassi, G., & Veschi, V. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529847 · Cited by 52
Polymorphisms in the Human Inhibitory Signal-regulatory Protein α Do Not Affect Binding to Its Ligand CD47
Hatherley, D., Lea, S. M., Johnson, S., & Barclay, A. N. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.550558 · Cited by 51
SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells
Piccione, E. C., Juárez, S., Tseng, S., Liu, J., Stafford, M., Narayanan, C., Wang, L., Weiskopf, K., & Majeti, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2503 · Cited by 51
Self-citation
The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
Schürch, C. M., Forster, S., Bruehl, F. K., Yang, S. H.-Y., Felley‐Bosco, E., & Hewer, E. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373235 · Cited by 51
Regulatory Role of Quiescence in the Biological Function of Cancer Stem Cells
Lee, S. H., Reed-Newman, T. C., Anant, S., & Ramasamy, T. S. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10031-8 · Cited by 51
Siglecs as Therapeutic Targets in Cancer
Lim, J., Sari, D., & Bagga, T. (2021) · Biology · doi:10.3390/biology10111178 · Cited by 54
Concise Review: Leukemia Stem Cells in Personalized Medicine
Guzmán, M. L., & Allan, J. N. (2013) · Stem Cells · doi:10.1002/stem.1597 · Cited by 52
Acute myelogenous leukemia stem cells: From Bench to Bedside
Rico, J. F., Hassane, D. C., & Guzmán, M. L. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.034 · Cited by 54
Macrophages in multiple myeloma: emerging concepts and therapeutic implications
Asimakopoulos, F. A., Kim, J., Denu, R. A., Hope, C. L., Jensen, J. L., Ollar, S. J., Hebron, E., Flanagan, C. E., Callander, N. S., & Hematti, P. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.778409 · Cited by 51
Apoptosis and non-inflammatory phagocytosis can be induced by mitochondrial damage without caspases
van Delft, M. F., Smith, D. P., Lahoud, M. H., Huang, D. C. S., & Adams, J. M. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.166 · Cited by 50
The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy
Ravindran, S., Rasool, S., & Maccalli, C. (2019) · Cancer Microenvironment · doi:10.1007/s12307-019-00233-1 · Cited by 49
Regulation of cancer stem cell activities by tumor-associated macrophages.
Jinushi, M., Baghdadi, M., Chiba, S., & Yoshiyama, H. (2012) · Europe PMC (PubMed Central) · Cited by 49
miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation ofDHFR, integrins, andCD47
Yang, S. Y., Choi, S. A., Lee, J. Y., Park, A.-K., Wang, K., Phi, J. H., Koh, E. J., Park, W., Park, S., Hwang, D. W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6227 · Cited by 49
BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
Liu, F., Jiang, C. C., Yan, X. G., Tseng, H., Wang, C. Y., Zhang, Y. Y., Yari, H., La, T., Farrelly, M. L., Guo, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17704 · Cited by 50
Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6-dependent manner
Peña‐Martínez, P., Eriksson, M. D., Ramakrishnan, R., Chapellier, M., Högberg, C., Orsmark‐Pietras, C., Richter, J., Andersson, A., Fioretos, T., & Järås, M. (2017) · Leukemia · doi:10.1038/leu.2017.261 · Cited by 49
Homing of ICG-loaded liposome inlaid with tumor cellular membrane to the homologous xenografts glioma eradicates the primary focus and prevents lung metastases through phototherapy
Xu, H., Shen, B., Lin, M., Tong, M., Zheng, Y., Jiang, X., Yang, W., Yuan, J., Yao, Q., & Zhao, Y. (2018) · Biomaterials Science · doi:10.1039/c8bm00604k · Cited by 49
Subtype-Based Prognostic Analysis of Cell-in-Cell Structures in Early Breast Cancer
Zhang, X., Niu, Z., Qin, H., Fan, J., Wang, M., Zhang, B., Zheng, Y. Y., Gao, L., Chen, Z., Tai, Y., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00895 · Cited by 49
CD47-targeted bismuth selenide nanoparticles actualize improved photothermal therapy by increasing macrophage phagocytosis of cancer cells
Guo, Z., Liu, Y., Zhou, H., Zheng, K., Wang, D., Jia, M., Xu, P., Ma, K., Cui, C., & Wang, L. (2019) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2019.110546 · Cited by 48
The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance
Mola, S., Pandolfo, C., Sica, A., & Porta, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186866 · Cited by 48
Lactate‐Responsive Gene Editing to Synergistically Enhance Macrophage‐Mediated Cancer Immunotherapy
Li, Y., Yue, W., Huang, Y., Qin, G., Zhao, C., Ren, J., & Qu, X. (2023) · Small · doi:10.1002/smll.202301519 · Cited by 48
Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma
Goto, H., Kojima, Y., Matsuda, K., Kariya, R., Taura, M., Kuwahara, K., Nagai, H., Katano, H., & Okada, S. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.03.004 · Cited by 48
Antibody therapy for acute myeloid leukaemia
Gasiorowski, R., Clark, G. J., Bradstock, K. F., & Hart, D. N. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12691 · Cited by 48
Monoclonal Antibodies Against Human Cancer Stem Cells
Naujokat, C. (2014) · Immunotherapy · doi:10.2217/imt.14.4 · Cited by 48
Animal models of leukemia: any closer to the real thing?
Cook, G., & Pardee, T. S. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9405-5 · Cited by 55
Ovarian and cervical cancer patient derived xenografts: The past, present, and future
Boone, J. D., Dobbin, Z. C., Straughn, J. M., & Buchsbaum, D. J. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.022 · Cited by 50

Authors: Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L.
Affiliations: Stanford Medicine (US)
Institute for Stem Cell Biology and Regenerative Medicine (US)
Stanford University (US)
Corresponding author: Majeti, Ravindra
Weissman, Irving L.
ORCID: Majeti, Ravindra
Chao, Mark P.
Alizadeh, Ash A.
Pang, Wendy W.
Jaiswal, Siddhartha
Gibbs, Kenneth D.
Weissman, Irving L.
Venue: Cell
Publisher: Elsevier BV
Published: 2009-07
Volume: 138
Issue: 2
Pages: 286-299
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2009.05.045
PMC: PMC2726837
OpenAlex: W2097126393
Cited by: 1,752
References: 47
Citations by year: 2026: 73 · 2025: 143 · 2024: 149 · 2023: 183 · 2022: 147 · 2021: 163 · 2020: 142 · 2019: 106 · 2018: 86 · 2017: 108 · 2016: 78 · 2015: 85 · 2014: 61 · 2013: 65 · 2012: 67
FWCI: 22.72
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1477 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Howard Hughes Medical Institute
National Cancer Institute (R01 CA86017, R01CA086017, T32CA009302)
National Institute of Allergy and Infectious Diseases (T32AI007290)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
Keywords: CD47, acute myeloid leukemia, leukemia stem cells, prognostic factors, anti-CD47 monoclonal antibody, phagocytosis, overall survival, engraftment, targeted therapy
MeSH terms: Animals, Antibodies, Monoclonal, Humans, Phagocytosis, Prognosis, Receptors, Immunologic, Leukemia, Myeloid, Acute, Mice, CD47 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks